The aim of the present study was to provide new mechanistic insight into the effect of pitavastatin at low dose on NF-κB activated by TNF-α in the human breast cancer cell line (MCF-7). We found that treatment of MCF-7 with 1 µM pitavastatin inhibited the proliferation and suppressed the nuclear expression of NF-κB p65 induced by TNF-α with Western blotting. Furthermore, EMSA showed that pitavastatin significantly reduced the DNA binding activity of NF-κB induced by TNF-α. Subsequently, luciferase assay revealed that pitavastatin (1 µM) inhibited the transcriptional activity of the NF-κB promoter, which was clearly related to the HMG-CoA reductase activity because addition of mevalonic acid (MEV) could elevate the NF-κB activity. Moreover, the Rho kinase inhibitor Y27632 abolished the effect of pitavastatin on NF-κB activity. Finally, the addition of TNF-α significantly increased IL-6 protein production, which was suppressed by the addition of pitavastatin. These results suggest that pitavastatin at low dose (1 µM) inhibits NF-κB activation and decreases IL-6 production induced by TNF-α. It is dependent on Rho kinase pathway in human breast cancer cells.

Related Articles